GeoVax Labs, Inc. (GOVX)
Largest Insider Buys in Sector
GOVX Stock Price History Chart
GOVX Stock Performance
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership …
Insider Activity of GeoVax Labs, Inc.
Over the last 12 months, insiders at GeoVax Labs, Inc. have bought $40,921 and sold $0 worth of GeoVax Labs, Inc. stock.
On average, over the past 5 years, insiders at GeoVax Labs, Inc. have bought $46,191 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: DODD DAVID A (President, CEO) — $35,381. Reynolds Mark (CFO) — $5,540.
The last purchase of 8,000 shares for transaction amount of $15,600 was made by DODD DAVID A (President, CEO) on 2024‑08‑09.
List of Insider Buy and Sell Transactions, GeoVax Labs, Inc.
| 2024-08-09 | President, CEO | 8,000 0.1589% | $1.95 | $15,600 | +31.02% | |||
| 2024-02-22 | President, CEO | 8,209 0.431% | $2.27 | $18,663 | -7.08% | |||
| 2024-02-21 | President, CEO | 520 0.0257% | $2.15 | $1,118 | -7.27% | |||
| 2024-02-07 | CFO | 2,000 0.0718% | $2.77 | $5,540 | -18.41% | |||
| 2023-12-22 | Chief Medical Officer | 6,944 0.0257% | $0.36 | $2,500 | +458.02% | |||
| 2023-09-25 | Chief Medical Officer | 9,653 0.0371% | $0.52 | $5,020 | +218.67% | |||
| 2023-08-25 | President, CEO | 35,087 0.1351% | $0.57 | $20,000 | +161.61% | |||
| 2023-08-18 | CFO | 10,000 0.038% | $0.52 | $5,179 | +171.84% | |||
| 2023-04-24 | President, CEO | 32,000 0.122% | $0.64 | $20,445 | -10.61% | |||
| 2023-04-20 | CFO | 8,000 0.0297% | $0.63 | $5,040 | -11.90% | |||
| 2022-09-21 | director | 10,000 0.043% | $1.10 | $11,000 | -39.22% | |||
| 2022-07-01 | VP, Business Development | 1,000 0.0043% | $0.82 | $820 | -6.48% | |||
| 2022-06-27 | Chief Medical Officer | 4,464 0.0367% | $1.12 | $5,000 | -28.60% | |||
| 2022-06-21 | 10,000 0.0761% | $1.21 | $12,100 | -38.32% | ||||
| 2022-05-05 | Chief Medical Officer | 9,722 0.0758% | $0.72 | $7,000 | +11.57% | |||
| 2022-05-04 | Chief Medical Officer | 4,999 0.0362% | $0.71 | $3,549 | +5.19% | |||
| 2011-12-30 | CSO Emeritus | 149,254 <0.0001% | $0.67 | $100,000 | ||||
| 2011-12-30 | President, CEO | 112,000 <0.0001% | $0.67 | $75,040 | ||||
| 2011-12-30 | CFO | 15,000 <0.0001% | $0.67 | $10,050 | ||||
| 2010-07-02 | CFO | 1,000 <0.0001% | $2.50 | $2,500 |
Insider Historical Profitability
| DODD DAVID A | President, CEO | 26661 0.2825% | $2.34 | 9 | 0 | <0.0001% |
| Reynolds Mark | CFO | 7213 0.0764% | $2.34 | 9 | 0 | <0.0001% |
| ROBINSON HARRIET L | CSO Emeritus | 1201226 12.7302% | $2.34 | 5 | 8 | |
| Tsolinas Peter M | director | 431734 4.5754% | $2.34 | 1 | 0 | |
| CHASE RANDAL D | director | 36613 0.388% | $2.34 | 2 | 0 | <0.0001% |